Jakafi gets approval from FDA over treatment of patients with Polycythemia Vera

December 6, 2014 12:19 PM

15 0

The US Food and Drug Administration (FDA) has approved Incyte Corporation's Jakafi (ruxolitinib) for the treatment of patients with polycythemia vera (PV).

Jakafi is an oral medication and the first and only product approved by the FDA for PV, a rare and progressive blood cancer.

Read more

To category page